How the interaction occurs:
Some medicines may lower the amount of dabigatran or edoxaban in your blood.
What might happen:
Your dabigatran or edoxaban may not work as well and your risk of an unwanted blood clot may increase.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor and pharmacist) know that you are taking these medicines together, if you have taken carbamazepine, phenytoin, rifampin, or St. John's wort in the previous week, or if you stop taking carbamazepine, phenytoin, rifampin, or St. John's wort. Your doctor may want to change you to a different medication to prevent blood clots, or adjust the dose of your dabigatran or edoxaban.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Pradaxa (dabigatran etexilate mesylate) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. September, 2014.
2.Pradaxa (dabigatran etexilate mesilate) UK summary of product characteristics. Boehringer Ingelheim Limited August 18, 2011.
3.Pradax (dabigatran etexilate mesilate) Canadian prescribing information. Boehringer Ingelheim June 13, 2011.
4.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
5.Savaysa (edoxaban) US prescribing information. Daiichi Sankyo, Inc January, 2015.
6.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..